Mereo BioPharma Group plc financial data

Symbol
MREO on Nasdaq
Industry
Pharmaceutical Preparations
Location
One Cavendish Place, Fourth Floor, London, United Kingdom
State of incorporation
United Kingdom
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 13, 2024

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 769M shares
Entity Public Float 144M USD
Common Stock, Value, Issued 3.03M USD
Weighted Average Number of Shares Outstanding, Basic 712M shares +13.3%
Weighted Average Number of Shares Outstanding, Diluted 712M shares +13.3%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 0 USD -100%
Research and Development Expense 4.95M USD +33.2%
General and Administrative Expense 7.87M USD +195%
Operating Income (Loss) -12.8M USD -1480%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -12.3M USD -600%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -12.3M USD -600%
Earnings Per Share, Basic -0.02 USD/shares
Earnings Per Share, Diluted -0.02 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 87.4M USD
Assets, Current 93.9M USD
Property, Plant and Equipment, Net 338K USD
Operating Lease, Right-of-Use Asset 985K USD
Intangible Assets, Net (Excluding Goodwill) 1.09M USD
Assets 96.1M USD
Accounts Payable, Current 2.7M USD
Accrued Liabilities, Current 3.72M USD
Liabilities, Current 15.5M USD
Operating Lease, Liability, Noncurrent 552K USD
Other Liabilities, Noncurrent 536K USD
Liabilities 17.5M USD
Accumulated Other Comprehensive Income (Loss), Net of Tax -18.3M USD
Retained Earnings (Accumulated Deficit) -441M USD
Stockholders' Equity Attributable to Parent 78.7M USD +58.4%
Liabilities and Equity 96.1M USD

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.99M USD +13.6%
Net Cash Provided by (Used in) Investing Activities -700K USD -67.1%
Common Stock, Shares, Issued 769M shares
Common Stock, Par or Stated Value Per Share 0 GBP/shares
Interest Paid, Excluding Capitalized Interest, Operating Activities 4K USD -99.4%
Deferred Tax Assets, Valuation Allowance 206M USD +4.61%
Deferred Tax Assets, Gross 206M USD +4.61%
Operating Lease, Liability 1.23M USD
Depreciation 100K USD 0%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -12.3M USD -3390%
Lessee, Operating Lease, Liability, to be Paid 1.35M USD
Property, Plant and Equipment, Gross 1.22M USD
Operating Lease, Liability, Current 679K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Deferred Tax Assets, Operating Loss Carryforwards 111M USD +5.46%
Operating Lease, Payments 193K USD +1.05%
Additional Paid in Capital 535M USD
Amortization of Intangible Assets 108K USD +68.8%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Operating Leases, Future Minimum Payments Due 1.54M USD
Interest Expense 331K USD -67.8%